BioSpace News Archive

Drug Development

Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies

Replimune Group, Inc. today announced updated data from completed cohorts of the Phase 2 part of the IGNYTE clinical trial in non-melanoma skin cancer (NMSC) and melanoma.

March 30, 2022
·
16 min read
Business

Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform

Orchard Therapeutics today announced its intention to focus its hematopoietic stem cell (HSC) gene therapy platform exclusively on severe neurometabolic diseases and early research programs while also reporting its financial results for the quarter and year ended December 31, 2021.

March 30, 2022
·
18 min read
Business

Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth

Omega Therapeutics, Inc. today announced the appointment of Kevin McManus as Chief Human Resources Officer and Ling Zeng, Esq., as Chief Legal and Administrative Officer.

March 30, 2022
·
8 min read
Deals

Amylyx Pharmaceuticals Stock Trading Halted Today

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Nasdaq has halted trading of the company’s common stock.

March 30, 2022
·
2 min read
Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022

Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022.

March 30, 2022
·
6 min read
Business

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

CureVac N.V. today announced that first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.

March 30, 2022
·
7 min read
Drug Development

Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA

Biogen Inc. (Nasdaq: BIIB) has submitted the final study protocol for the confirmatory Phase 4 ENVISION trial to the U.S. Food and Drug Administration (FDA) for review and approval.

March 30, 2022
·
8 min read
Business

CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results

Centogene N.V. today announced financial results for the fourth quarter and fiscal year ended December 31, 2021, and provided a business update.

March 30, 2022
·
10 min read
Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

Numinus Wellness Inc. is pleased to announce that it has advanced to the next implementation phase in the clinical trial.

March 30, 2022
·
4 min read
Business

Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Axcella Therapeutics today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

March 30, 2022
·
10 min read